harmPharma stocks to buy: Sun Pharma, Ajanta Pharma, Ipca Labs, Mankind Pharma and Acutaas Chemicals are likely to be key pharmaceutical companies to deliver strong results for the second quarter of the financial year 2026-27, according to InCred Equities latest report.
The brokerage remains bullish on Acutaas, Mankind Pharma and Ipca Labs, as it sees up to 49.89% upside in these pharma stocks. However, companies like Dr Reddy's Labs, Divi's Labs, Lupin, Cipla, Torrent Pharma, and Blue Jet Healthcare may see some pressure in Q2FY27, as per InCred experts.
Pharmaceutical companies are expected to fare better in the second quarter of FY27, with Sun Pharma, Ajanta Pharma, Ipca Labs, Mankind Pharma, and Acutaas Chemicals likely to be among top performers.
Reported numbers by these companies is likely to continue to benefit from the Indian Rupee depreciation for export-oriented players, noted InCred Equities while highlighting that input costs will remain the margin watch as high freight costs persist.
The brokerage gave an ‘Add’ rating to the stock with a target price of ₹4757 per share. The company combines a visible CDMO pipeline with new businesses now ramping, “which makes it our preferred name among the API and CDMO companies in 2QFY27,” stated the brokerage in its report.